



Universiteit
Leiden
The Netherlands

Chronic pancreas allograft rejection followed by successful HLA-incompatible islet alloautotransplantation: a novel strategy?

Veltkamp, D.M.J.; Nijhoff, M.F.; Broek, D.A.J. van den; Buntinx, M.; Kers, J.; Engelse, M.A.; ... ; Vries, A.P.J. de

Citation

Veltkamp, D. M. J., Nijhoff, M. F., Broek, D. A. J. van den, Buntinx, M., Kers, J., Engelse, M. A., ... Vries, A. P. J. de. (2023). Chronic pancreas allograft rejection followed by successful HLA-incompatible islet alloautotransplantation: a novel strategy? *Transplant International*, 36. doi:10.3389/ti.2023.11505

Version: Publisher's Version
License: [Creative Commons CC BY 4.0 license](https://creativecommons.org/licenses/by/4.0/)
Downloaded from: <https://hdl.handle.net/1887/3720706>

Note: To cite this publication please use the final published version (if applicable).



OPEN ACCESS

***Correspondence:**

Aiko P. J. de Vries
a.p.j.de_vries@lumc.nl

†ORCID:

Denise M. J. Veltkamp
orcid.org/0000-0001-9914-7827

Michiel F. Nijhoff
orcid.org/0000-0002-5131-2237

Dennis A. J. van den Broek
orcid.org/0000-0001-7135-4752

Maren Buntinx
orcid.org/0000-0003-0402-0255

Jesper Kers
orcid.org/0000-0002-2418-5279

Marten A. Engelse
orcid.org/0000-0003-1341-8521

Volkert A. L. Huurman
orcid.org/0000-0002-7162-1467

Dave L. Roelen
orcid.org/0000-0002-1846-1193

Sebastiaan Heidt
orcid.org/0000-0002-6700-188X

Ian P. J. Alwayn
orcid.org/0000-0003-0603-9849

Eelco J. P. de Koning
orcid.org/0000-0002-1232-7022

Aiko P. J. de Vries
orcid.org/0000-0002-9284-3595

Received: 22 April 2023

Accepted: 08 August 2023

Published: 24 August 2023

Citation:

Veltkamp DMJ, Nijhoff MF, van den Broek DAJ, Buntinx M, Kers J, Engelse MA, Huurman VAL, Roelen DL, Heidt S, Alwayn IPJ, de Koning EJP and de Vries APJ (2023) Chronic Pancreas Allograft Rejection Followed by Successful HLA-Incompatible Islet Alloautotransplantation: A Novel Strategy?
Transpl Int 36:11505.
doi: 10.3389/ti.2023.11505

Chronic Pancreas Allograft Rejection Followed by Successful HLA-Incompatible Islet Alloautotransplantation: A Novel Strategy?

Denise M. J. Veltkamp^{1,2†}, Michiel F. Nijhoff^{1,2,3†}, Dennis A. J. van den Broek^{1,2†}, Maren Buntinx^{4†}, Jesper Kers^{2,5†}, Marten A. Engelse^{1,2†}, Volkert A. L. Huurman^{2,6†}, Dave L. Roelen^{2,7†}, Sebastiaan Heidt^{2,7†}, Ian P. J. Alwayn^{2,6†}, Eelco J. P. de Koning^{1,2,3†} and Aiko P. J. de Vries^{1,2*†}

¹Division of Nephrology, Department of Medicine, Leiden University Medical Center, Leiden, Netherlands, ²Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands, ³Division of Endocrinology and Metabolism, Department of Medicine, Leiden University Medical Center Leiden, Leiden, Netherlands, ⁴Department of Dermatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Pathology, Leiden University Medical Center, Leiden, Netherlands, ⁶Department of Transplant Surgery, Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Immunology, Leiden University Medical Center, Leiden, Netherlands

The purpose of pancreas or islet transplantation is to restore glycemic control in order to mitigate diabetes-related complications and prevent severe hypoglycemia. Complications from chronic pancreas allograft rejection may lead to transplantectomy, even when the endocrine function remains preserved. We present first evidence of a successful HLA incompatible islet re-transplantation with islets isolated from a rejecting pancreas allograft after simultaneous kidney pancreas transplantation. The pancreas allograft was removed because of progressively painful pancreatic panniculitis from clinically uncontrolled chronic rejection. The endocrine function was preserved. Induction treatment for this “islet alloautotransplantation” consisted of plasmapheresis, IVIg and alemtuzumab. At 1 year, the patient retained islet graft function with good glycemic control and absence of severe hypoglycemia, despite persistent low-grade HLA donor-specific antibodies. His panniculitis had resolved completely. In our point of view, islet alloautotransplantation derived from a chronically rejecting pancreas allograft is a potential option to salvage (partial) islet function, despite preformed donor-specific antibodies, in order to maintain stable glycemic control. Thereby it protects against severe hypoglycemia, and it potentially mitigates kidney graft dysfunction and other diabetes-related complications in patients with continued need for immunosuppression and who are otherwise difficult to retransplant.

Keywords: antibody-mediated rejection, donor specific antigen (DSA), islet transplantation, re-transplantation, simultaneous kidney pancreas transplantation

Abbreviations: ABMR, Antibody-mediated rejection; CMV, Cytomegalovirus; C-peptide, Connecting peptide; DSA, Donor-specific antibody; HLA, Human leukocyte antigen; IEQ, Islet equivalent; IVIg, Intravenous immunoglobulin; MFI, Median fluorescence intensity; MMTT, Mixed-meal tolerance test; SPK, Simultaneous pancreas and kidney transplantation; T1D, Type 1 diabetes; TCMR, T cell-mediated rejection.

INTRODUCTION

The purpose of pancreas or islet transplantation is to restore glycemic control in order to mitigate diabetes-related complications and prevent severe hypoglycemia. Whole pancreas transplantation has become a successful strategy since the 1960s in patients with type 1 diabetes in need of a kidney transplantation, or who otherwise have life-threatening glycemic control to warrant the impact of maintenance immunosuppression [1].

However, long-term outcomes after simultaneous pancreas-kidney (SPK) transplantation have not improved evidently in past decades, amongst others due to chronic rejection [2, 3]. Antibody-mediated rejection (ABMR) is increasingly recognized as a cause of chronic rejection in the setting of pancreas transplantation as well [3–5]. Chronic rejection is often refractory to anti-rejection therapy resulting in complications such as bleeding, duodenal perforation, and fistula/abscess formation. This may necessitate pancreatectomy despite preserved endocrine function, as pancreatic rejection is often more targeted to exocrine tissue, (micro)vasculature, or duodenum [6, 7]. Re-transplantation following sensitization becomes increasingly difficult, as pancreas allocation in the Eurotransplant area is not primarily based on HLA matching and patients are often no longer eligible (e.g., age >50–55 years, comorbidity), by the time a suitable offer becomes available, leaving them with labile diabetes again. Since the turn of the century, islet transplantation has become a less invasive alternative for whole pancreas transplantation with clinical merit to prevent severe hypoglycemia in labile diabetes as well as improved metabolic control compared to an optimized insulin regimen, especially in patients who are already on maintenance immunosuppression [8]. We previously described the option of alloautotransplantation, a strategy to preserve endogenous insulin production by isolating and re-transplanting the islets after an allograft pancreatectomy [7]. However, evidence for HLA incompatible islet alloautotransplantation from a chronically rejecting pancreas transplant has not been described before to our knowledge.

Here we present the 1 year results of an HLA incompatible islet re-transplantation after graft pancreatectomy in a patient with progressively painful panniculitis from a clinically uncontrolled chronic rejection of the pancreas (and kidney) allograft with preserved endocrine function.

EVIDENCE


The evidence concerns a non-sensitized (virtual panel-reactive antibody; vPRA 0%) 50 year-old cytomegalovirus (CMV) seronegative male with a medical history of poorly controlled type 1b diabetes (T1D) and end-stage renal disease. The patient was diagnosed with type 1 diabetes at 8 years of age after a presentation of ketoacidosis. He was negative for anti-GAD, anti-IA-2 and anti-ZnT8 at time of referral and had undetectable C-peptide since childhood (<0.01 nmol/L). With a flexible four times daily insulin regimen (on average 0.8 units/kg daily), he

suffered from recurrent hypoglycemia and poor glycemic control (HbA1c 90.3 mmol/mol Hb). The patient underwent SPK transplantation from an HLA-mismatched (2-2-2) CMV seronegative donor after cardiac death. The patient provided written consent for publication.

At SPK transplantation his immunosuppressive regimen consisted of alemtuzumab induction 30 mg s.c. and methylprednisolone 500 mg once, followed by tacrolimus 5 mg b.i.d., mycophenolate mofetil 750 mg b.i.d., and prednisolone 10 mg q.d. The postoperative course (**Figure 1**) was complicated, amongst others, by delayed renal allograft function and an unexpected primary CMV infection for which valganciclovir was initiated. Due to development of leukopenia and later BK-viremia, mycophenolate mofetil was discontinued and tacrolimus tapered.

In the period from eight to 11 months posttransplant, two clinical episodes of pancreas rejection occurred each with right lower quadrant abdominal tenderness, graft pancreatitis on radiological imaging, a concomitant increase in serum amylase/lipase, and *de-novo* HLA donor-specific antibodies (DSAs) (immunodominant DQB1*05:02-DQA1*01:02 with low median fluorescence intensity (MFI) of 997 at 8 months and 943 at 11 months, and anti-DP4 with MFI 1800 at 11 months), measured with Luminex single antigen bead assays from LifeCodes (Immucor). Alternative causes of pancreatitis such as constipation, CMV relapse, and re-occurrence of T1D auto-antibodies were ruled out. A pancreas or, alternatively, a kidney allograft biopsy was not performed at first, as pancreas biopsy is not routine practice at our center due to experienced risk of complications, and kidney graft function initially remained stable. However, a kidney graft biopsy at 11 months, performed because of *de-novo* proteinuria (2.90 g/24 h), showed mixed-type chronic active T cell-mediated rejection (TCMR) and ABMR rich in plasma cells with negative staining for CMV, BK-virus (SV40), and C4d (**Figure 2A**). Both clinical rejection episodes were treated with methylprednisolone 1 g q.d. for 3 days only. However, second-line therapy (lymphocyte depleting antibodies) was withheld because of contraindications at that time (leukopenia and active viral complications: BK-viremia (8 months), and COVID-19 (11 months)). Pancreatectomy was considered but a watchful waiting strategy was chosen since endocrine function remained intact and no other complications were immediately evident. At 8 months, everolimus 0.75 mg b.i.d. was started next to tacrolimus to consolidate the first-line rejection treatment by pulsed steroids to control chronic rejection in the context of BK-virus reactivation and leukopenia. At 11 months, everolimus was substituted by mycophenolate mofetil because of proteinuria, which then improved. As complication of high-dose corticosteroids, vertebral compression fractures of the thoracic spine occurred.


At 20 months post SPK transplantation, progressively painful subcutaneous nodules on both lower legs developed (**Figure 2C**) necessitating opioid maintenance. A punch skin biopsy showed pancreatic panniculitis (**Figure 2B**), likely as complication of ongoing chronic pancreas allograft rejection, which has been described incidentally before in transplant recipients [9]. Since



efficacy of second-line therapy is questionable for long-standing chronic (or mixed-type) rejection and because of progressive complications, pancreatectomy was deemed favorable over a third round of methylprednisolone or escalation with second-line therapy now that contraindications were absent [6]. Nonetheless, the pancreas' endocrine function remained intact (HbA1c 38.5 mmol/mol, random C-peptide 1.6 nmol/L, glucose 5.4 mmol/L, without insulin therapy). As the patient was adamant to preserve his endocrine function 21 months after SPK transplantation, an islet allograft transplantation was performed after pancreatectomy despite presence of (low-grade) DSAs. Before islet transplantation, a single round of plasma exchange was performed followed by intravenous immunoglobulin (IVIg) (1 g/kg). Alemtuzumab (15 mg s.c.) induction, methylprednisolone (500 mg day -1 , 250 mg day 0, 125 mg day $+1$) and etanercept (50 mg s.c. day 0, 25 mg s.c. days 2/6/10) were prescribed following standard practice for allogeneic islet transplantation according to local protocol. At the operating room, directly after pancreatectomy the pancreas was flushed on the backtable using Ringer's acetate solution supplemented with 5 mmol/L calcium at pH 7.35 prior to static cold storage transport to the islet isolation laboratory. Islet isolation was performed according to previously published protocols [10–14]. Macroscopically, the pancreas looked edematous but non-necrotic. With iodine and penicillin-streptomycin solution the pancreas was decontaminated. The pancreas was infused with 1 vial (2533 IU) collagenase solution combined with one vial of neutral protease

solution (200 IU) (both Serva NB-1® (Serva Electrophoresis GmbH, Heidelberg, Germany) in Ringer's acetate solution supplemented with 5 mmol/L calcium at pH 7.35. Gentamycin, ciprofloxacin, vancomycin and amphotericin B were added to all fluids in the isolation's procedure. In the final product, both the gram staining and the endotoxin test were negative. The islets were re-transplanted intraportally directly after the isolation procedure. The allograft contained 313000 Islet equivalents (IEQ) (4013 IEQ/kg patient) in a volume of 12 mL with a purity of 6%. Strict glycemic control was maintained by continuous intravenous insulin (glucose target 4–7 mmol/L) for 48 h, after which s.c. insulin was recommenced to maintain the tight glycemic target.

At 15 weeks after this islet allograft transplantation, the patient was treated with 8 units of long-acting insulin once daily. Time-in-range of glucose concentrations was 96% (3.9–10 mmol/L; as measured by Flash Glucose Monitoring) with an HbA1c of 42.7 mmol/mol. Maximum C-peptide was 2.32 nmol/L (maximum glucose 12.4 mmol/L) during a 2 h mixed-meal tolerance test (MMTT). One year after the islet allograft transplantation the patient retained islet graft function with absence of severe hypoglycemia. At that time, he used metformin/dapagliflozin 850mg b.i.d. combined with 20 units of long-acting insulin a day, with which he had a time-in-range of 80%–90% and an estimated HbA1c of 48 mmol/mol. Baseline C-peptide was 0.30 nmol/L with glucose of 4.1 mmol/L, and rose to 1.01 nmol/L with a maximum glucose of 9.1 mmol/L during the



MMTT. Together, this amounts to clinical treatment success as defined by a “good” function according to the Igl criteria, a beta score of 5, and a BETA-2 score of 13.55 [15]. Anti-GAD, anti-IA-2 and anti-ZnT8 remained negative and kidney function clinically stable (creatinine 134 $\mu\text{mol/L}$ with an albumin/creatinine ratio of 30.3 mg/mmol). The panniculitis recovered completely. The preformed immunodominant DSA DQB1*05:02-DQA1*01:02 remained present at 1 year with a MFI of 1180. Anti-DP4 remained undetectable after the islet alloautotransplantation.

DISCUSSION

This report describes 1 year evidence of a successful (according to the Igl criteria) islet alloautotransplantation in a patient with preformed HLA-DSAs after allograft pancreatectomy for likely chronic rejection of the pancreas. Although we did not obtain histological evidence, the fact that a clinical syndrome of pancreatitis occurred twice (localized pain, rise in pancreatic enzymes, and edematous pancreas at imaging) after a period of immunosuppressive underexposure with development of a dnDSA made a clinical diagnosis of pancreas rejection likely. Non-alloimmune causes of pancreatitis were excluded albeit that the unexpected primary CMV infection may have contributed since CMV has been associated with heterologous immunity [16]. After reconfirming seronegativity of donor and recipient, it remains unknown how the CMV infection occurred. A kidney biopsy during the second episode of pancreatitis

showed mixed chronic-active TCMR and ABMR further corroborating the likelihood of rejection.

Although some discordancy for rejection (12.5% kidney-only rejections) has been observed by Parajuli et al., that study did not stratify for clinical context such as simultaneous pancreas dysfunction and presence of DSA [17]. A study by Uva et al. showed that a positive renal biopsy for rejection correctly predicts pancreatic rejection in 86% of cases with concurrent pancreatic dysfunction, albeit they also did not stratify by presence of DSA [18]. Furthermore, there is debate whether discordancy truly exists or whether it's merely a matter of time [19, 20]. Our report illustrates the timely development from a single episode of clinical pancreatitis with DSA formation to recurrent pancreatitis, to eventually kidney transplant dysfunction with biopsy proven chronic mixed type ABMR and a biopsy-proven panniculitis to underscore the likelihood of chronic pancreas rejection. At the time, active viral complications and leukopenia contraindicated escalation to second-line therapy, such as ATG or alemtuzumab, to have improved rejection control [21]. Notably, the pancreas graft's endocrine capacity appeared relatively unaffected by the pancreatitis episodes perhaps also questioning the likelihood of rejection. However, distinctive rejection patterns of pancreatic endocrine and exocrine cells have been described before, yet the pathophysiological mechanism is not completely clear. It might be reflective of differential HLA expression [22]. Exocrine tissue and the pancreas (micro)vasculature are often the primary targets of rejection, whereas islets remain relatively unaffected. Pancreatitis

from chronic (acinar) rejection might subsist by ongoing release of inflammatory danger signals, such as proteases, from continued pancreatitis. The persistent acinar damage and chronic vascular injury might trigger a progressive fibrogenic reaction that could eventually impair β -cell function [22]. The painful complication of the progressive pancreatic panniculitis, first described by Chiari in 1883, is not completely understood, but is thought to be subcutaneous fat necrosis from circulating proteases and enzymes released from an inflamed pancreas, which necessitated the use of opioids in our case [9, 23]. A pancreas transplantectomy and re-transplanting the islets, when endocrine function remains largely preserved, could theoretically break the vicious cycle. From our point of view, the precise etiology of the pancreatitis does not diminish the observation that it is possible to perform an islet allotransplantation in the context of a low-grade DSA in patients with limited access to transplantation. The patient's vPRA had increased to 87% making him an unlikely candidate for pancreas re-transplantation at his age or for HLA compatible islet transplantation. Islets are thought not to express HLA class II, except under conditions of stress/inflammation [3]. We therefore removed present antibodies using plasma exchange and IVIg before islet allotransplantation in order to create a "window of opportunity before DSA recurrence" to infuse islets that could have upregulated HLA class II expression due to stress of isolation and culture, instant blood-mediated inflammatory reaction, or hypoxia. Islets are relatively protected from DSAs once vascularized due to endothelial chimerism and vascular sequestration of DSAs [24]. Notably, a recent single-center study, published after our case occurred, showed favorable outcomes of allogeneic islet transplantation in the presence of preformed DSAs, questioning in hindsight the necessity for pretransplant plasma exchange and IVIg [25]. Low-grade DSA convey excellent outcome [26].

Before deciding to perform the islet allotransplantation, we discussed whether to treat the likely pancreas allograft rejection with a third round of methylprednisolone and a postponed second-line treatment for chronic (or mixed-type) ABMR, which consists of alemtuzumab, plasma exchange, and/or IVIg at our center. Viral complications (BK-viremia, COVID-19) had prohibited escalation before. However, we felt that efficacy of such therapy for longer-standing chronic active perhaps antibody-mediated pancreas rejection would be questionable and that, given the progressive complications (panniculitis) necessitating chronic use of opioids, a more definite solution was warranted. The persistent immunodominant HLA-DSA DQB1*05:02-DQA1*01:02 at 1 year post-islet allotransplantation suggests indeed that second-line treatment would not have made the DSA disappear. Although speculative, we also hypothesized that taking away the subsisting inflammatory stimulus (exocrine tissue rejection/pancreatitis) would likely increase the chance of a more sustained response to novel induction treatment and better preserve his kidney function considering his highly-immunized status [27]. A limitation of this point of view is that an auto-immune etiology of his type-1 diabetes could not be established (no detectable auto-antibodies), which

might have contributed to a more favorable outcome of the islet transplantation.

CONCLUSION

Successful islet allotransplantation from a likely chronically rejecting pancreas with preserved endocrine function is possible to salvage (partial) β -cell function after pancreatectomy. Preformed low-grade DSAs are not necessarily a contraindication. This strategy may be considered to prevent relapse of inadequate glycemic control with recurrent severe hypoglycemic events and have improved metabolic control with better preserved kidney transplant function, when there is ongoing need for immunosuppression and the patient is an unlikely candidate for pancreas re-transplantation.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.

ETHICS STATEMENT

Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

DV: concept/design and drafting article; MN: critical review of the article and supervision; DB: critical review of the article; MB: critical review of the article concerning the panniculitis and providing clinical pictures of the panniculitis; JK: critical review of the article and providing pathology pictures; ME: critical review of the article; VH: critical review of the article; DR: critical review of the article and performing immunoassays; SH: critical review of the article and performing immunoassays; IA: critical review of the article; EK: critical review of the article and supervision; AV: concept/design, critical review of the article and supervision. All authors contributed to the article and approved the submitted version.

CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

1. Freise CE, Narumi S, Stock PG, Melzer JS. Simultaneous Pancreas-Kidney Transplantation: An Overview of Indications, Complications, and Outcomes. *West J Med* (1999) 170(1):11–8.
2. Waki K, Terasaki PI, Kadowaki T. Long-Term Pancreas Allograft Survival in Simultaneous Pancreas-Kidney Transplantation by Era: UNOS Registry Analysis. *Diabetes Care* (2010) 33(8):1789–91. doi:10.2337/dc09-2276
3. Drachenberg CB, Torrealba JR, Nankivell BJ, Rangel EB, Bajema IM, Kim DU, et al. Guidelines for the Diagnosis of Antibody-Mediated Rejection in Pancreas Allografts-Updated Banff Grading Schema. *Am J Transpl* (2011) 11(9):1792–802. doi:10.1111/j.1600-6143.2011.03670.x
4. de Kort H, Munivenkatappa RB, Berger SP, Eikmans M, van der Wal A, de Koning EJ, et al. Pancreas Allograft Biopsies With Positive C4d Staining and Anti-Donor Antibodies Related to Worse Outcome for Patients. *Am J Transpl* (2010) 10(7):1660–7. doi:10.1111/j.1600-6143.2010.03079.x
5. Boggi U, Vistoli F, Andres A, Arbogast HP, Badet L, Baronti W, et al. First World Consensus Conference on Pancreas Transplantation: Part II - Recommendations. *Am J Transpl* (2021) 21:17–59. doi:10.1111/ajt.16750
6. Colvin RB. Antibody-Mediated Renal Allograft Rejection: Diagnosis and Pathogenesis. *J Am Soc Nephrol* (2007) 18(4):1046–56. doi:10.1681/ASN.2007010073
7. Nijhoff MF, Dubbeld J, van Erkel AR, van der Boog PJM, Rabelink TJ, Engelse MA, et al. Islet Allograft Transplantation: Allogeneic Pancreas Transplantation Followed by Transplant Pancreatectomy and Islet Transplantation. *Am J Transpl* (2018) 18(4):1016–9. doi:10.1111/ajt.14593
8. Vantghem MC, de Koning EJP, Pattou F, Rickels MR. Advances in β -Cell Replacement Therapy for the Treatment of Type 1 Diabetes. *Lancet* (2019) 394(10205):1274–85. doi:10.1016/S0140-6736(19)31334-0
9. Beveridge M, Pei S, Tsoukas MM. Pancreatic Panniculitis in a Pancreas-Kidney Transplant Patient Resolved After Immunosuppression Increase: Case Report and Review of Literature. *JAAD Case Rep* (2015) 1(2):101–5. doi:10.1016/j.jdc.2015.02.006
10. Shapiro AMJ, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP, et al. International Trial of the Edmonton Protocol for Islet Transplantation. *New Engl J Med* (2006) 355(13):1318–30. doi:10.1056/NEJMoa061267
11. Matsumoto S, Noguchi H, Naziruddin B, Onaca N, Jackson A, Nobuyo H, et al. Improvement of Pancreatic Islet Cell Isolation for Transplantation. *Baylor Univ Med Cent Proc* (2007) 20(4):357–62. doi:10.1080/08998280.2007.11928323
12. Friberg AS, Ståhle M, Brandhorst H, Korsgren O, Brandhorst D. Human Islet Separation Utilizing a Closed Automated Purification System. *Cel Transplant* (2008) 17(12):1305–13. doi:10.3727/096368908787648100
13. Ricordi C, Lacy PE, Finke EH, Olack BJ, Scharp DW. Automated Method for Isolation of Human Pancreatic Islets. *Diabetes* (1988) 37(4):413–20. doi:10.2337/diab.37.4.413
14. Nijhoff MF, Engelse MA, Dubbeld J, Braat AE, Ringers J, Roelen DL, et al. Glycemic Stability Through Islet-After-Kidney Transplantation Using an Alemtuzumab-Based Induction Regimen and Long-Term Triple-Maintenance Immunosuppression. *Am J Transpl* (2016) 16(1):246–53. doi:10.1111/ajt.13425
15. Rickels MR, Stock PG, de Koning EJP, Piemonti L, Pratschke J, Alejandro R, et al. Defining Outcomes for β -Cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop. *Transpl Int* (2018) 31(4):343–52. doi:10.1111/tri.13138
16. Heutinck KM, Yong SL, Tonneijck L, van den Heuvel H, van der Weerd NC, van der Pant KAMI, et al. Virus-Specific CD8(+) T Cells Cross-Reactive to Donor-Alloantigen Are Transiently Present in the Circulation of Kidney Transplant Recipients Infected With CMV And/or EBV. *Am J Transpl* (2016) 16(5):1480–91. doi:10.1111/ajt.13618
17. Parajuli S, Arpali E, Astor BC, Djamali A, Aziz F, Redfield RR, et al. Concurrent Biopsies of Both Grafts in Recipients of Simultaneous Pancreas and Kidney Demonstrate High Rates of Discordance for Rejection as Well as Discordance in Type of Rejection - A Retrospective Study. *Transpl Int* (2018) 31(1):32–7. doi:10.1111/tri.13007
18. Uva PD, Papadimitriou JC, Drachenberg CB, Toniolo MF, Quevedo A, Dotta AC, et al. Graft Dysfunction in Simultaneous Pancreas Kidney Transplantation (SPK): Results of Concurrent Kidney and Pancreas Allograft Biopsies. *Am J Transpl* (2019) 19(2):466–74. doi:10.1111/ajt.15012
19. Assalino M, Hadaya K, Andres A, Berney T. Discordant Rejection in Simultaneous Pancreas and Kidney Transplantation: True Discordance or Analysis Artefact? *Transpl Int* (2018) 31(1):17–9. doi:10.1111/tri.13017
20. Landstra CP, Nijhoff MF, Roelen DL, de Vries APJ, de Koning EJP. Diagnosis and Treatment of Allograft Rejection in Islet Transplantation. *Am J Transpl* (2023) 2023. doi:10.1016/j.ajt.2023.05.035
21. Aziz F, Parajuli S, Uddin S, Harrold K, Djamali A, Astor B, et al. How Should Pancreas Transplant Rejection Be Treated? *Transplantation* (2019) 103(9):1928–34. doi:10.1097/TP.0000000000002694
22. Drachenberg CB, Odorico J, Demetris AJ, Arend L, Bajema IM, Bruijn JA, et al. Banff Schema for Grading Pancreas Allograft Rejection: Working Proposal by a Multi-Disciplinary International Consensus Panel. *Am J Transpl* (2008) 8(6):1237–49. doi:10.1111/j.1600-6143.2008.02212.x
23. Chiari H. Ueber die Sogenannte Fettnekrose. *Prager Medicinische Wochenschrift* (1883) 8:285–6.
24. Chen CC, Pouliquen E, Broisat A, Andreato F, Racapé M, Bruneval P, et al. Endothelial Chimerism and Vascular Sequestration Protect Pancreatic Islet Grafts From Antibody-Mediated Rejection. *J Clin Invest* (2018) 128(1):219–32. doi:10.1172/JCI93542
25. Maanaoui M, Chetboun M, Top I, Elsermans V, Kerr-Conte J, Le Mapihan K, et al. The Challenge of HLA Donor Specific Antibodies in the Management of Pancreatic Islet Transplantation: An Illustrative Case-Series. *Sci Rep* (2022) 12(1):12463. doi:10.1038/s41598-022-16782-3
26. Pouliquen E, Baltzinger P, Lemle A, Chen CC, Parissiadias A, Borot S, et al. Anti-Donor HLA Antibody Response After Pancreatic Islet Grafting: Characteristics, Risk Factors, and Impact on Graft Function. *Am J Transpl* (2017) 17(2):462–73. doi:10.1111/ajt.13936
27. Lablanche S, Vantghem MC, Kessler L, Wojtuszczyńska A, Borot S, Thivolet C, et al. Islet Transplantation Versus Insulin Therapy in Patients With Type 1 Diabetes With Severe Hypoglycaemia or Poorly Controlled Glycaemia After Kidney Transplantation (TRIMECO): A Multicentre, Randomised Controlled Trial. *Lancet Diabetes Endocrinol* (2018) 6(7):527–37. doi:10.1016/S2213-8587(18)30078-0

Copyright © 2023 Veltkamp, Nijhoff, van den Broek, Buntinx, Kers, Engelse, Huurman, Roelen, Heidt, Always, de Koning and de Vries. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.